Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy-Reference-Cited by-同舟云学术

Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy

Published:2016-11-07 Issue:4 Volume:77 Page:839-850
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Wang Xiaohong,Schoenhals Jonathan E.,Li Ailin,Valdecanas David R.,Ye Huiping,Zang Fenglin,Tang Chad,Tang Ming,Liu Chang-Gong,Liu Xiuping,Krishnan Sunil,Allison James P.,Sharma Padmanee,Hwu Patrick,Komaki Ritsuko,Overwijk Willem W.,Gomez Daniel R.,Chang Joe Y.,Hahn Stephen M.,Cortez Maria Angelica,Welsh James W.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 193 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism of immune activation mediated by genomic instability and its implication in radiotherapy combined with immune checkpoint inhibitors;Radiotherapy and Oncology;2024-10

2. Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors;Cancer Immunology, Immunotherapy;2024-09-13

3. Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy;Journal of Experimental & Clinical Cancer Research;2024-09-02

4. Recent developments in immunotherapy for gastrointestinal tract cancers;Journal of Hematology & Oncology;2024-08-09

5. Immune checkpoint inhibitors and radiotherapy in gastrointestinal cancer treatment;Український радіологічний та онкологічний журнал;2024-07-02